Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Curetis   /   Curetis/Opgen : RSS en dan verder?

Aandeel OpGen OTC:OPGN.Q, US68373L5057

Vertraagde koers (usd) Verschil Volume
1,960   0,000   (0,00%) Dagrange 0,000 - 0,000 0   Gem. (3M) 44,2K

Curetis/Opgen : RSS en dan verder?

Volgen
38 Posts
Pagina: «« 1 2 | Laatste | Omlaag ↓
  1. forum rang 4 Pitmans 16 juni 2023 11:24
    Aangezien we weer vrij langdurig onder de $1 bivakkeren, vrees ik dat de volgende non-compliance notice van Nasdaq er alweer aan zit te komen.
    Een nieuwe RSS binnen 1 jaar ?

    Zoals wel vaker bij deze parel, mocht die voorbeurs-winst ook in de daghandel doorzetten, probeer je momentje te timen en stap uit (en eventueel lager weer in).
    Ook gisteren nabeurs overigens al 20+% hogere koersen, reden onbekend. Willen ze misschien een RSS voorkomen ? Mijn verkooporder staat, op $ 1,03 voor een klein winstje.
  2. DAGEVOS 16 juli 2023 19:25
    om mijn ongenoegen te laten blijken heb ik als blijk van ongenoegen en een signal daarvan 10000aandelen voor 1 ct in de bied gezet.
    wat een bagger dit aandeel. veel beloven weinig geven laat de gek in vreugde leven.
    als er een positief bericht komt pompen ze de koers extreem op en halen zo weer veel nieuwe slachtoffers binnen. dat is de enige reden van die extreme uitschieters en heeft niets te maken met vooruitzichten van het bedrijf.
  3. p/o 11 augustus 2023 00:03
    pijnlijk

    As previously reported, and in light of the Company’s business performance and current cash position, the Company does not expect that its current cash will be sufficient to fund operations beyond September 2023. Since the end of the second quarter, the Company has pursued options to improve its cash position or mitigate a liquidity shortfall. Nevertheless, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. The Company continues to consider all alternatives, including restructuring or refinancing its debt, seeking additional debt or equity capital, reducing or delaying the Company’s business activities, selling assets, and other strategic transactions or other measures, including obtaining relief under U.S. as well as applicable foreign bankruptcy laws. There is no guarantee that the Company will be able to identify and execute on any of these alternatives or that any of them will be successful.
  8. forum rang 10 DeZwarteRidder 12 oktober 2023 22:35
    OpGen Shares Surge Sixfold Amid Strategic Transaction Talks
    EditorVenkatesh JartarkarStock Markets
    Published Oct 12, 2023 11:27AM ET

    OpGen Shares Surge Sixfold Amid Strategic Transaction Talks © Reuters.

    OPGN
    +173.81%

    Shares in OpGen (NASDAQ:OPGN), the precision-medicine firm, surged sixfold in premarket trading on Thursday, following the announcement of strategic transaction talks with an undisclosed investor. The company has entered into a private placement agreement as part of these discussions, selling $1 million in preferred stock to the investor.

    In a separate move aimed at bolstering its financial position, OpGen's Curetis unit has sold Unyvero A50 systems to another undisclosed strategic partner. This sale secured an advance payment of nearly $800,000 for the company.

    These financial maneuvers come at a crucial time for OpGen. The company has previously issued warnings about its dwindling cash reserves and raised doubts over its operational sustainability. By entering into these strategic transactions and securing significant advance payments, OpGen is taking the necessary steps to ensure its survival in the competitive precision-medicine sector.

    Yet, the company's financial health remains a concern. According to InvestingPro's real-time metrics, OpGen operates with a significant debt burden and is quickly burning through cash. The company's market cap stands at 21.89M USD, and it recorded a revenue of 2.82M USD in LTM2023.Q2, marking a decline of 31.25%. Its gross profit margin stood at -285.24%, reflecting weak gross profit margins.

    Furthermore, the company's stock price has seen significant volatility. It has fallen significantly over the last five years, with a year-to-date price total return of -88.09%. However, it has shown a strong return over the last month, with a one-month price total return of 52.73%.

    InvestingPro Tips suggests that the company's short-term obligations exceed its liquid assets, and analysts do not anticipate the company will be profitable this year. Despite these challenges, OpGen's stock price often moves in the opposite direction of the market, which could present unique investment opportunities.

    For more detailed insights and tips on OpGen and other companies, consider subscribing to InvestingPro. The platform offers 21 additional tips for OpGen, alongside real-time metrics and analysis for a wide range of companies.

    This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
  9. forum rang 4 Pitmans 15 november 2023 22:43
    Hmm, dit was natuurlijk bij niemand bekend ten tijde van het vorige PB :

    "Subsidiaries Curetis GmbH in Germany and Ares Genetics GmbH in Austria filed for insolvency under German and Austrian laws, respectively, in November 2023"

    en

    "The Company entered into two agreements in October 2023 to improve its cash position consisting of a preferred stock purchase agreement for $1.0 million in gross proceeds with a potential strategic investor and a warrant inducement agreement with an existing institutional investor that, as of November 14, 2023, resulted in gross proceeds of approximately $2.06 million. Nevertheless, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern."

    Alles bij elkaar is het eigenlijk gewoon einde verhaal :

    ROCKVILLE, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2023 financial and operating results.

    Third Quarter 2023 Financial Results of OpGen, Inc.

    Total revenue for the third quarter of 2023 was approximately $0.70 million compared to the Company’s revenue of approximately $0.45 million in the third quarter of 2022. Total revenue for the nine months ended September 30, 2023 was approximately $2.35 million compared to the Company’s revenue of approximately $1.89 million in the nine months ended September 30, 2022.

    Total operating expenses decreased in the third quarter of 2023 to approximately $4.26 million compared to approximately $13.96 million for the third quarter of 2022 primarily due to the Company’s goodwill impairment charge of $6.98 million recorded in the third quarter of 2022. Total operating expenses decreased by approximately 39% in the nine months ended September 30, 2023 to approximately $16.14 million compared to approximately $26.52 million for the same period in 2022.

    Cash and cash equivalents were approximately $0.29 million as of September 30, 2023, compared with approximately $7.44 million as of December 31, 2022.

    The Company entered into two agreements in October 2023 to improve its cash position consisting of a preferred stock purchase agreement for $1.0 million in gross proceeds with a potential strategic investor and a warrant inducement agreement with an existing institutional investor that, as of November 14, 2023, resulted in gross proceeds of approximately $2.06 million. Nevertheless, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. The Company continues to actively consider multiple alternatives, including, but not limited to, restructuring or refinancing its debt, seeking additional debt or equity capital, reducing or delaying business activities, selling assets, other strategic financings or transactions and other measures, including obtaining relief under applicable bankruptcy laws. There can be no assurance that the Company will be able to identify or execute on any of these alternatives on acceptable terms or that any of these alternatives will be successful.

    In the reporting quarter and year to date, the Company has seen the following key developments:

    OpGen implemented certain cash management initiatives, including restructuring its U.S. operations by reducing headcount from 23 to 6 and scaling down operations at OpGen’s U.S. headquarters to the core functions of a U.S. Nasdaq listed company with only minimal marketing and sales support, allowing the Company to conserve cash and focus on the functions needed to pursue potential strategic alternatives.

    In October 2023, OpGen amended its non-exclusive distribution agreement with Fisher Healthcare to allow Fisher Healthcare to sell to existing U.S. Unyvero customers of the Company, which had previously been maintained by the Company’s sales force.

    In October 2023, OpGen discontinued its FDA cleared Acuitas AMR Gene Panel diagnostic test.

    In October 2023, OpGen’s German subsidiary Curetis GmbH responded to all of the FDA’s additional requests with regard to Curetis' De Novo request for the Unyvero UTI urinary tract infection test in order to continue the FDA review.

    In October 2023, OpGen entered into a preferred stock purchase agreement with a potential strategic investor for gross proceeds of $1.0 million in exchange for 1,000 shares of the Company’s Series D Preferred Stock. In connection with the ongoing discussions for a transaction with such potential strategic investor, the parties anticipate closing the transaction under the preferred stock purchase agreement as soon as practical.

    On November 6, 2023, following OpGen’s unsuccessful efforts to sell the businesses or assets of its wholly owned subsidiaries Curetis GmbH and Ares Genetics GmbH or to access additional capital to continue their operations, Curetis GmbH and Ares Genetics GmbH filed for insolvency under the applicable German and Austrian laws, respectively.
  11. forum rang 4 Pitmans 20 mei 2024 10:28
    quote:

    Pitmans schreef op 16 juni 2023 11:24:

    Een nieuwe RSS binnen 1 jaar ?
    Soms zou ik willen dat ik vaker zo goed kon voorspellen.
    Een technisch failliet bedrijf dat al z'n (o zo succevol voorgestelde) activiteiten heeft verkocht en nu z'n lege beurshuls in stand houdt met een RSS in afwachting van een nieuwe scam om weer hetzelfde mee te gaan doen. Waar hebben we dat eerder gezien (meerdere malen) ?

    OpGen Announced 1-for-10 Reverse Stock Split - Thu, May 16, 2024, 1:00 PM GMT+24 min

    ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) today announced that the Company’s board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company’s existing trading symbol “OPGN.” The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 68373L505.

    OpGen expects that the Reverse Stock Split, which was approved by its stockholders at a Special Meeting held on May 9, 2024, will increase the market price per share of common stock in order to regain compliance with The Nasdaq Capital Market’s minimum bid price listing requirement of $1.00 per share.
  15. forum rang 10 DeZwarteRidder 20 augustus 2024 17:35
    quote:

    Pitmans schreef op 20 augustus 2024 16:52:

    Een roemloos einde :

    OpGen, Inc. (OPGN)
    NasdaqCM - NasdaqCM Real Time Price. Currency in USD

    1.96000.0000 (0.00%)
    As of August 19 04:00PM EDT. Market open.

    Delisting

    OPGN is delisted effective Aug. 20, 2024
    Opgen gaat gewoon naar de Pink Sheets.
  17. Netje 13 september 2024 08:34
    op 12 september 2024 staat Opgen op 2,08 Am. Dollars.
    De schommelingen van de aandelenkoers zijn dus de laatste tijd interessant.
    Ik kan bij mijn bank wel Opgen verkopen maar niet aankopen, alhoewel opgen nog een handelsvolume van een paar duizend aandelen per dag heeft.

    Opgen zelf liet weten dat zij hun bedrijf herfinanceren en een nieuwe aanvraag zullen/hebben ingediend om terug op de Nasdaq komen te staan.

    Bericht van 22 augustus 2024:
    "OpGen (OPGN) just unveiled an announcement.

    OpGen, Inc. has entered into a financing agreement with AEI Capital Ltd., allowing the sale of up to $3 million in common stock, with the company controlling the timing and amount of sales. This move comes as OpGen faces delisting from Nasdaq due to non-compliance with the minimum stockholders’ equity requirement. Despite a denied request for continued listing, the company settled outstanding debts and expects that the new financing will help regain compliance. OpGen plans to appeal the delisting decision and pursue additional steps to meet Nasdaq’s requirements, but there is no guarantee of success. The company’s forward-looking statements carry risks and uncertainties that could affect their financial outcomes."
  18. forum rang 10 DeZwarteRidder 13 september 2024 08:42
    quote:

    Netje schreef op 13 september 2024 08:34:

    op 12 september 2024 staat Opgen op 2,08 Am. Dollars.
    De schommelingen van de aandelenkoers zijn dus de laatste tijd interessant.
    Ik kan bij mijn bank wel Opgen verkopen maar niet aankopen, alhoewel opgen nog een handelsvolume van een paar duizend aandelen per dag heeft.

    Opgen zelf liet weten dat zij hun bedrijf herfinanceren en een nieuwe aanvraag zullen/hebben ingediend om terug op de Nasdaq komen te staan.

    Bericht van 22 augustus 2024:
    "OpGen (OPGN) just unveiled an announcement.

    OpGen, Inc. has entered into a financing agreement with AEI Capital Ltd., allowing the sale of up to $3 million in common stock, with the company controlling the timing and amount of sales. This move comes as OpGen faces delisting from Nasdaq due to non-compliance with the minimum stockholders’ equity requirement. Despite a denied request for continued listing, the company settled outstanding debts and expects that the new financing will help regain compliance. OpGen plans to appeal the delisting decision and pursue additional steps to meet Nasdaq’s requirements, but there is no guarantee of success. The company’s forward-looking statements carry risks and uncertainties that could affect their financial outcomes."
    Wees maar blij dat je dit rampenfonds niet kan kopen.........!!!!
38 Posts
Pagina: «« 1 2 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee